Breaking News

GenomOncology and Genomenon Partner to Bring Genomic Literature Search to Molecular Tumor Board

GenomOncology’s Tumor Board Puts Up-to-Date Research at Oncologists Fingertips

GenomOnocology and Genomenon® announced today a partnership that incorporates Mastermind® Genomic Search Engine results into GenomOncology’s Molecular Tumor Board. The goal of the partnership is to put the most up-to-date genomic research at the fingertips of oncologists making treatment decisions for critically ill cancer patients.

GenomOncology’s Molecular Tumor Board software is designed to support a fully integrated workflow from case creation, “smart” content for the clinician based on the patient’s alterations, therapy and clinical trial recommendations to generation of a report for sign-off by the oncologist. The platform has advanced capabilities such as automatic parsing and loading of any NGS panel including whole exome-whole genome, the ability to integrate IHC, FISH, cytogenetics and any number of clinical data elements to trigger highly tailored therapy and clinical trial recommendations using its proprietary match algorithm.

With this partnership, GenomOncology has embedded Mastermind search results in their platform exactly when oncologists are reviewing the results of an NGS panel to enable them to quickly determine whether a patient’s mutation has ever been found in the medical literature, and quickly access research about the mutation. The search results are automated based on the patient’s specific set of alterations.

Genomenon’s Mastermind Genomic Search Engine powers evidence-based precision medicine by connecting patient DNA with the scientific research required to diagnose and treat cancer and rare diseases. Mastermind has the world’s largest index of medical articles cataloguing the genetic relationships between DNA and human diseases. 

“We know oncologists need to make timely decisions for patients, but are extremely pressed for time and overwhelmed with the amount of information out there. Providing them tools to make that easier is critical, especially as the field of oncology continues to change rapidly. Integrating Genomenon’s Mastermind is one of the ways we are doing this. We are excited to bring continued innovation to our customers through this partnership” said Manuel Glynias, Founder and CEO of GenomOncology.

“Precision medicine is about putting the best tools, information, and knowledge about the patient’s tumor into the hands of the experts to provide the best medical treatment for cancer patients” said Mike Klein, CEO of Genomenon.  “We’re thrilled to be partnering with GenomOncology to make the most comprehensive and up-to-date cancer research available to oncologists when they are making treatment decisions.” 

Genomenon and GenomOncology will be exhibiting at the annual meeting of the Association for Molecular Pathology (AMP) on November 1-3, 2018 in San Antonio, Texas.

About Team | NewsPatrolling

Comments are closed.

Scroll To Top